LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Hierro, Natalia"
  2. AU="Gary Newnam"
  3. AU="Zornitsa Mitkova"
  4. AU="Nicholas Tadros"
  5. AU="Ntelkis, Nikolaos"
  6. AU=Pitrou Isabelle
  7. AU="Ouwehand, Willem"
  8. AU=Glover Natasha M.
  9. AU=Guo Zhinian
  10. AU="Alison M. Lee"
  11. AU="Walcher, Felix"
  12. AU=Marupudi Neena I.
  13. AU="Earp, Karly M"
  14. AU="Zeng, Hui Hui"
  15. AU="Marco Pallecchi"
  16. AU=Marcus Adam I
  17. AU="Martin, Phillip"
  18. AU=Ouyang Yi-Bing
  19. AU="Tam, Patrick Chung Kay"
  20. AU="Patrick R. H. Steinmetz"
  21. AU="Odierna, Francesco"
  22. AU="Monteiro, Valter" AU="Monteiro, Valter"
  23. AU=Konkel Alex
  24. AU="Alnakib, Yasir"
  25. AU=Tallerico Rossana
  26. AU=Scherer Kai
  27. AU="Cao, Guiyun"
  28. AU="Zarrouki, Youssef"
  29. AU="Abayomi, Akin"
  30. AU=Kpatcha Tchazou
  31. AU=Glaeser Robert M
  32. AU="Mioara Cristea"
  33. AU="Turiegano, Enrique"
  34. AU="Russcher, H"
  35. AU="Lim, Kean-Jin"
  36. AU="Spurek, Monika"
  37. AU="Giulia A. Zamboni"

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel: Midnight Cortisol is Associated with Changes in Systolic Blood Pressure and Diabetic Neuropathy in Subjects with Type 1 Diabetes Undergoing Simultaneous Kidney-Pancreas Transplantation.

    Boswell, Laura / Amor, Antonio J / Montagud-Marrahi, Enrique / Casals, Gregori / Díaz-Catalan, Daniela / Banon-Maneus, Elisenda / Ramírez-Bajo, María José / Hierro, Natalia / Diekmann, Fritz / Musquera, Mireia / Serés-Noriega, Tonet / Esmatjes, Enric / Ferrer-Fàbrega, Joana / Ventura-Aguiar, Pedro / Hanzu, Felicia A

    Diabetes therapy : research, treatment and education of diabetes and related disorders

    2023  Band 15, Heft 1, Seite(n) 165–181

    Abstract: Introduction: An increased midnight cortisol (MC) has been described in end-stage kidney disease (ESKD) and type 1 diabetes (T1D). Lower circulating levels of the cytokine soluble tumor necrosis factor (TNF)-like weak inducer of apoptosis (sTWEAK) have ... ...

    Abstract Introduction: An increased midnight cortisol (MC) has been described in end-stage kidney disease (ESKD) and type 1 diabetes (T1D). Lower circulating levels of the cytokine soluble tumor necrosis factor (TNF)-like weak inducer of apoptosis (sTWEAK) have been found in T1D and ESKD and associated with cardiovascular (CV) events in the latter. We aimed to study MC and sTWEAK in simultaneous pancreas-kidney transplant (SPKT) recipients, and the association of these markers with CV risk factors and transplant outcomes.
    Methods: This was a retrospective cohort study including subjects with T1D who received a first SPKT between 2008 and 2020. MC and sTWEAK at baseline were correlated with CV risk factors and evolution 1 year after SPKT.
    Results: We included 29 subjects (58.6% women, mean age 43.5 ± 7.5 years, diabetes duration 31.9 ± 9.4 years). Systolic blood pressure (SBP) increased directly with MC quartiles, despite similar hypertension prevalence (p < 0.05). At 1 year, antihypertensive treatment was deintensified in those in lower MC quartiles (p < 0.05). Diabetic neuropathy prevalence decreased progressively in higher cortisol quartiles (p for trend = 0.005). Low MC was associated with delayed kidney graft function (p for trend = 0.044), and high sTWEAK with kidney graft rejection (p for trend = 0.018). In multivariate analyses, MC (standardized-β 0.505, p = 0.004) and age (standardized-β - 0.460, p = 0.040) were independently correlated with SBP, and MC was independently associated with the presence of diabetic neuropathy (OR 0.633, 95% CI 0.425-0.944, p = 0.025), adjusted for confounders.
    Conclusions: In this exploratory study, lower MC was associated with a lower baseline SBP, an improvement of antihypertensive treatment 1 year after transplant, and a higher diabetic neuropathy prevalence in SPKT recipients.
    Sprache Englisch
    Erscheinungsdatum 2023-11-02
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2566702-6
    ISSN 1869-6961 ; 1869-6953
    ISSN (online) 1869-6961
    ISSN 1869-6953
    DOI 10.1007/s13300-023-01487-1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Donor-derived Cell-free DNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-kidney Transplantation.

    Ventura-Aguiar, Pedro / Ramirez-Bajo, Maria Jose / Rovira, Jordi / Bañón-Maneus, Elisenda / Hierro, Natalia / Lazo, Marta / Cuatrecasas, Miriam / Garcia-Criado, M A / Liang, Nathan / Swenerton, Ryan K / Cofan, Federic / Cucchiari, David / Esforzado, Nuria / Montagud-Marrahi, Enrique / Oppenheimer, Federic / Piñeiro, Gaston / Revuelta, Ignacio / Torregrosa, Vicens / Ahmed, Ebad /
    Soboleva, Karina / Kaur, Navchetan / Zimmermann, Bernhard G / Al Haj Baddar, Nour / Demko, Zachary P / Escrig, Cesar / Tabriziani, Hossein / Gauthier, Philippe / Billings, Paul R / Amor, Antonio J / Ferrer, Joana / Campistol, Josep M / Diekmann, Fritz

    Transplantation

    2022  Band 106, Heft 8, Seite(n) 1690–1697

    Abstract: Background: Pancreas graft status in simultaneous pancreas-kidney transplant (SPKTx) is currently assessed by nonspecific biochemical markers, typically amylase or lipase. Identifying a noninvasive biomarker with good sensitivity in detecting early ... ...

    Abstract Background: Pancreas graft status in simultaneous pancreas-kidney transplant (SPKTx) is currently assessed by nonspecific biochemical markers, typically amylase or lipase. Identifying a noninvasive biomarker with good sensitivity in detecting early pancreas graft rejection could improve SPKTx management.
    Methods: Here, we developed a pilot study to explore donor-derived cell-free DNA (dd-cfDNA) performance in predicting biopsy-proven acute rejection (P-BPAR) of the pancreas graft in a cohort of 36 SPKTx recipients with biopsy-matched plasma samples. dd-cfDNA was measured using the Prospera test (Natera, Inc.) and reported both as a fraction of the total cfDNA (fraction; %) and as concentration in the recipient's plasma (quantity; copies/mL).
    Results: In the absence of P-BPAR, dd-cfDNA was significantly higher in samples collected within the first 45 d after SPKTx compared with those measured afterward (median, 1.00% versus 0.30%; median, 128.2 versus 35.3 cp/mL, respectively with both; P  = 0.001). In samples obtained beyond day 45, P-BPAR samples presented a significantly higher dd-cfDNA fraction (0.83 versus 0.30%; P  = 0.006) and quantity (81.3 versus 35.3 cp/mL; P  = 0.001) than stable samples. Incorporating dd-cfDNA quantity along with dd-cfDNA fraction outperformed dd-cfDNA fraction alone to detect active rejection. Notably, when using a quantity cutoff of 70 cp/mL, dd-cfDNA detected P-BPAR with a sensitivity of 85.7% and a specificity of 93.7%, which was more accurate than current biomarkers (area under curve of 0.89 for dd-cfDNA (cp/ml) compared with 0.74 of lipase and 0.46 for amylase).
    Conclusions: dd-cfDNA measurement through a simple noninvasive blood test could be incorporated into clinical practice to help inform graft management in SPKTx patients.
    Mesh-Begriff(e) Biomarkers ; Cell-Free Nucleic Acids/genetics ; Graft Rejection/diagnosis ; Graft Rejection/genetics ; Humans ; Kidney Transplantation/adverse effects ; Pancreas Transplantation/adverse effects ; Pilot Projects ; Postoperative Complications ; Tissue Donors
    Chemische Substanzen Biomarkers ; Cell-Free Nucleic Acids
    Sprache Englisch
    Erscheinungsdatum 2022-03-14
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000004088
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang